Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like NAAS trade halted earlier today. Now at $7.33. Seems like you lucked out?
what a huge mistake just touched $10.00
NAAS
could be enjoy over there.
What is happening back there in America. Why is the market falling? Poland and these Baltic countries are booming. Wonder if all that USA money Biden is sending over here is going into the right pockets
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
NAAS hits $7.14 hod man did I sell early there.
ok I just meant I hoped you weren't in higher because of the dip I'm still watching g/l
This is Bottom Swing Plays Chat, right? Recent Bottom Swing on SLS was a brief dip to $0.81 (for about 2 minutes) a few weeks back. Didn't get that.
I'm buying SLS now because
1. Phase 3 Regal Trial data imminent for drug GPS.
2. In the last 30 days, their drug SLS009 has received two (2) Priority Review Vouchers for Rare Pediatic Disease Designation (RPDD) because the drug has a 99%+ overall response rate in patients.
3. Commercial team left in March 2024. Company is looking to be bought out and actively seeking such. Abbvie, Merck, Novartis are my guesses for interested parties.
I hope your in alot lower :+)
I'm 200,000 shares long right now.
wow good news and huge drop.
thxs for the heads up watching
Added SLS again at $1.10 today. Awaiting Phase 3 REGAL trial Interim Analysis (IA) when the 60th event (typically death of patient, relapse of patient).
Glad I got out also.
UVIX gdog
Member Level
Re: gdog post# 1612
Wednesday, May 29, 2024 9:35:35 AM
Post#
1653
of 1761
5-29 S UVIX $6.88 flat
I'm not sure on Nasdaq but i think they may get bought out. I added small but thats sure ont a reco. Sounds like your having a great time enjoy.
What is the news on ALLR? Is it going to get NASDAQ approval. Maybe I should double down one more time at this pps.
What about UVIX? $4.95. Dam, I'm glad I got out when I diid.
From zakopane poland.
I got a huge chunk….With powder in case it dips on delisting…
https://stocktwits.com/Daylas/message/579259341
Allr I added 5k today at .1942
goofed up on DQ I took profit at 15.29 and knew it was going ti still go but I was up a pretty good amount anyhow its 16.00 now lol
when I place a date and a B it means I maybe buying and when I place a date and a S it means I maybe selling, these posts are not meant as a recomendation to buy or sell a stock I post about.
Missed PRGO @ $ 24.82 watched all day thinking I buy at the close and all of a sudden it took like a cat shot in the butt lol
nbix ya I looked after your mention wow
I hope so, too. There's no reason to do one if on OTC for now. Just let their drug testing speak for the future. If it is a winner, then getting back on NASDAQ will be easy.
I will hold it since they are reporting good results on their testing. I just remember NBIX
I hope they don't do another r/s I'll take the otcqx
sic but not bailing it wouldn't take much to have a .25 cnet bounce.
Looks like ALLR is a goner on NASDAQ
May be it will find new life on OTC.
Right along side NLST both are now in the 60% loss range!
TR wow up another 9% today
sheesh the shrts are trying their best to bankrupt this little company Iadded small at .30 gulp
Guess I guessed wrong and should have waited!
They say that they will be delisted on June 27.
On June 18, 2024, we received a written notice form Nasdaq notifying us that we failed to comply with the Minimum Bid Price Rule. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Rule. However, we are not eligible for any compliance period specified in Rule 5810(c)(3)(A) because we effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Accordingly, the Nasdaq staff determined to delist our securities from Nasdaq (the “Staff Determination”). Unless we request an appeal of the Staff Determination, trading of our shares of common stock will be suspended at the opening of business on June 27, 2024, and a Form 25-NSE will be filed with the SEC, which will remove our securities from listing and registration on Nasdaq. We intend to request a hearing before a Nasdaq Hearings Panel (the “Panel”), to appeal the Staff Determination, which request would stay any delisting action pending the issuance of the Panel’s determination.
hopefully this starts the turn around on share price. ALLR
Oh my gosh I just looked up the ticker, sorry it didn't work. I had a million shares of ticker couv a few yrs back under a penny. I sold when it hit 3 cents it then went to .87 cents before they figure out it was a scam and halted sheesh that would have been $870,000.00
I guess it happens to all of us.
Well, it helped me just buy 300 @ .34 to get my even 1000 shares.
Reminds me of a stock I owned many years ago: NBIX
It was doing a similar trail on a drug for women.
It has a rough beginning and stock price fell
I had 8000 shares was trading it between $2 & $6.
I traded it one time to many, the pps shot up and I couldn't get back.
I was waiting for it to fall back but it never did.
And the rest is history of what could have been.
Boston ( June 25 , 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have been on treatment for more than 30 weeks.
The continued durability of clinical benefit further bolsters the Company’s announcement in early May 2024 that stenoparib had shown clear clinical benefit, including significant tumor shrinkage and long-term disease stability, in patients who had been heavily pre-treated for their ovarian cancer and otherwise have limited life expectancy. These results provided clinical proof of concept for stenoparib as a treatment in this patient population, prompting the company to halt patient enrollment to focus its resources on developing a follow-on trial designed to accelerate the path for stenoparib toward regulatory approval.
maybe this will help
Allarity Therapeutics Announces Multiple Patients In Its Phase 2 Stenoparib Trial Have Exceeded 30 Weeks On Treatment
Yea, just be glad you didn't buy at the top!
ALLR has a 52-week high of $269.80 and a 52-week low of $0.32.
That is some fall.
Maybe it can just get 1/3 the way back up
glad I sold news a/h 300m sale convertible note
I tried to short but couldn't get my order if fast enought lol
It was on the SEC site. So I guess that may be why talk of RS. I may add a few hundred more if it goes much lower to get me to 1000 shares. Then go on my trip next week and hope when I come back in October it has risen from the grave along with NLST and all my other downer stocks like SOFI.
I added small I'm riding this out.
I'm seeing talk on stock twitts about an rs why would they do an rs when there is only 77m Outstanding?
Allr has been posting this for the last month
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementGlobeNewswire | 05/20/2024
where did you find that?
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On June 18, 2024, Allarity Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has not complied with the Nasdaq Listing Rule 5550(a)(2) which is the requirement that for 30 consecutive business days the bid price for the Company’s common stock close above the $1 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.
The Company intends to request a hearing before a Nasdaq Hearings Panel (the “Panel”) at which it will request continued listing pending its return to compliance. The Company’s hearing request will stay the suspension of trading and delisting of the Company’s common stock pending the conclusion of the hearing process. Consequently, the Company expects its common stock to remain listed on the Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel will grant the Company’s request for a suspension of delisting or continued listing on the Nasdaq Capital Market.
I am looking too' I can only think that something must have failed in their new drug.
I'm looking so far I can't find anything
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
382
|
Created
|
05/14/24
|
Type
|
Free
|
Moderator gdog | |||
Assistants 100lbStriper Daylas Redoocs |
Posts Today
|
0
|
Posts (Total)
|
382
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |